Praxis Precision's Vormatrigine Fails Primary Endpoint in POWER1 Study, Future Trial Paused
PRAX has more than doubled off its 52-week low of $36.3.
Summary
Praxis Precision's vormatrigine failed to meet the primary endpoint in its Phase 2/3 POWER1 study for focal onset seizures. While the drug showed a 50% response rate and good tolerability, the company has paused enrollment in the follow-up POWER2 study to reassess the program. This is a significant setback for the vormatrigine pipeline, following a series of positive clinical and regulatory updates for other drug candidates and a strong Q1 financial report. The company's reassessment of the vormatrigine program will be critical.
At the time of this announcement, PRAX was trading at $335.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3B. The 52-week trading range was $36.30 to $366.52. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.